CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Purpose Lysine-specific demethylase 1 (LSD1) was highly expressed in several malignancies and had been implicated in pathological processes of cancer cells. However, the role of LSD1 in colorectal cancer (CRC) carcinogenesis, prognosis and treatment remains uncharacterized.Methods In this study, we examined LSD1 expression in paraffin-embedded CRC specimens from 295 patients, including 65 patients with paired samples of colorectal carcinoma, adjacent adenoma and normal colorectal tissues. Using an LSD1 inhibitor, CBB1003, as a probe, we studied the association between LSD1 and leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a CRC stem cell marker involved in carcinogenesis. The anti-tumor effects of CBB1003 on CRC cells were also examined.Results LSD1 expression was significantly elevated in colorectal tumor tissues compared with adjacent adenoma and normal colorectal tissues (P < 0.001), and LSD1 levels were significantly correlated with an advanced AJCC T stage (P = 0.012) and distant metastasis (P = 0.004). CBB1003 inhibited CRC cell proliferation and colony formation. In cultured CRC cells, inhibiting LSD1 activity by CBB1003 caused a decrease in LGR5 levels while overexpression of LGR5 reduced CBB1003-induced cell death. We also observed the inactivation of β-catenin/TCF signaling after CBB1003 treatment, consistent with the positive correlations among LSD1, LGR5, β-catenin and c-Myc expression in human colon tumor and adenoma tissues.Conclusion Our result suggested that LSD1 overexpression promotes CRC development and that the LSD1 inhibitor inhibits CRC cell growth by down-regulating LGR5 levels and inactivates the Wnt/β-catenin pathway. Thus, LSD1 and its inhibitor might provide a new target or a useful strategy for therapy of CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, inhibiting Lysine Demethylase 1A (KDM1A; demethylase for H3K4 and H3K9) suppressed CRC cell proliferation through downregulation of the Wnt/β-catenin pathway [174].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [174]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012 · cited 1×
“Aberrant histone modifications have been shown to contribute to cancer initiation and progression by altering the pattern of gene transcription such as inactivating tumor suppressor genes (Konishi and Issa 2007) and by inducing genome instability due to direct effects in the higher order of chromatin, chromosome conde…”
BackgroundA human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087 · cited 1×
“The leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), also known as GPR49, belongs to the G-protein-coupled receptor family of proteins and is a target of Wnt signaling (O’Brien et al. 2007; Ricci-Vitiani et al. 2007; Visvader and Lindeman 2012).”
BackgroundHistone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998 · cited 1×
“The leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), also known as GPR49, belongs to the G-protein-coupled receptor family of proteins and is a target of Wnt signaling (O’Brien et al. 2007; Ricci-Vitiani et al. 2007; Visvader and Lindeman 2012).”
BackgroundCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166 · cited 1×
“Subsequent studies observed that intestinal tumors arise from LGR5positive cells, suggesting LGR5 marks intestinal cancer stem cells (Barker et al. 2009).”
BackgroundCancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287 · cited 2×
“The leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), also known as GPR49, belongs to the G-protein-coupled receptor family of proteins and is a target of Wnt signaling (O’Brien et al. 2007; Ricci-Vitiani et al. 2007; Visvader and Lindeman 2012).”
BackgroundDynamic Regulation of Histone Lysine Methylation by Demethylases
Shi, Y., & Whetstine, J. R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.010 · Cited by 707 · cited 1×
“It is composed of several domains, including a SWIRM domain, a conserved motif shared by many chromatin regulatory complexes, an amine oxidase domain and a Tower domain found in BRCA2 (Shi and Whetstine 2007; Mimasu et al. 2008; Yang et al. 2007).”
BackgroundSchenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Histone lysine demethylases: emerging roles in development, physiology and disease
Shi, Y. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2218 · Cited by 601 · cited 1×
“Lysine-specific demethylase 1 (LSD1), the first histone demethylase that was discovered as a flavin adenine dinucleotide (FAD)-dependent amine oxidase, catalyzes the demethylation of histone H3-K4 and K9 (Shi 2007; Shi et al. 2004; Forneris et al. 2008).”
BackgroundHayami, S., Kelly, J. D., Cho, H., Yoshimatsu, M., Unoki, M., Tsunoda, T., Field, H. I., Neal, D. E., Yamaue, H., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25349 · Cited by 489 · cited 2×
“The expression of LSD1 has been associated with tumor recurrence during therapy in various cancers (Lim et al. 2010; Hayami et al. 2011; Chen et al. 2007).”
BackgroundLim, S., Janzer, A., Becker, A., Zimmer, A., Schüle, R., Buettner, R., & Kirfel, J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp324 · Cited by 470 · cited 2×
“The expression of LSD1 has been associated with tumor recurrence during therapy in various cancers (Lim et al. 2010; Hayami et al. 2011; Chen et al. 2007).”
BackgroundSchulte, J. H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., Ora, I., Pajtler, K., Klein-Hitpass, L., Kuhfittig-Kulle, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1735 · Cited by 445
Huang, Y., Greene, E., Murray Stewart, T., Goodwin, A. C., Baylin, S. B., Woster, P. M., & Casero, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700720104 · Cited by 292
Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer
Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., & Song, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035065 · Cited by 273
Monoclonal Antibodies Against Lgr5 Identify Human Colorectal Cancer Stem Cells
Kemper, K., Prasetyanti, P. R., De Lau, W., Rodermond, H., Clevers, H., & Medema, J. P. (2012) · Stem Cells · doi:10.1002/stem.1233 · Cited by 257 · cited 2×
“determined that LGR5 is a functional human CRC stem cells (CSCs) marker (Kemper et al. 2012).”
BackgroundWang, J., Lu, F., Ren, Q., Sun, H., Xu, Z., Lan, R., Liu, Y., Ward, D., Quan, J., Ye, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0896 · Cited by 228 · cited 4×
“reported that LSD1 inhibition can suppress Oct4 expression in F9 cells (Wang et al. 2011).”
BackgroundInfluentialSelf-citationKauffman, E. C., Robinson, B. D., Downes, M. J., Powell, L. G., Lee, M. M., Scherr, D. S., Gudas, L. J., & Mongan, N. P. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20758 · Cited by 210 · cited 1×
“The dysregulation of LSD1 activity in human has already been confirmed in several cancers (Lim et al. 2010; Wu et al. 2012; Schenk et al. 2012; Lv et al. 2012; Kauffman et al. 2011; Schutle et al. 2009; Huang et al. 2007).”
BackgroundLGR5 Interacts and Cointernalizes with Wnt Receptors To Modulate Wnt/β-Catenin Signaling
Carmon, K. S., Lin, Q., Gong, X., Thomas, A., & Liu, Q. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00272-12 · Cited by 203 · cited 1×
“Carmon et al. (2012) reported that LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/βcatenin signaling.”
BackgroundThe histone LSD1 demethylase in stemness and cancer transcription programs
Amente, S., Lania, L., & Majello, B. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.05.002 · Cited by 202
Colorectal Cancer Epigenetics: Complex Simplicity
van Engeland, M., Derks, S., Smits, K. M., Meijer, G. A., & Herman, J. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.2319 · Cited by 199
Structural basis of histone demethylation by LSD1 revealed by suicide inactivation
Yang, M., Culhane, J. C., Szewczuk, L. M., Gocke, C. B., Brautigam, C. A., Tomchick, D. R., Machius, M., Cole, P. A., & Yu, H. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1255 · Cited by 178 · cited 1×
“It is composed of several domains, including a SWIRM domain, a conserved motif shared by many chromatin regulatory complexes, an amine oxidase domain and a Tower domain found in BRCA2 (Shi and Whetstine 2007; Mimasu et al. 2008; Yang et al. 2007).”
BackgroundLSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer
Ding, J., Zhang, Z.-M., Xia, Y., Liao, G.-Q., Pan, Y., Liu, S., Zhang, Y., & Yan, Z.-S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.364 · Cited by 175 · cited 1×
“(Ding et al. 2013) reported that LSD1 promotes metastasis of colon cancer cells by down-regulating the expression of CDH-1, the role of LSD1 in CRC stem cell has not been elucidated.”
BackgroundLSD1: oxidative chemistry for multifaceted functions in chromatin regulation
Forneris, F., Binda, C., Battaglioli, E., & Mattevi, A. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.01.003 · Cited by 165
Saif, M. W., & Chu, E. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181e076af · Cited by 156 · cited 1×
“Genetic alterations are important contributors to the multistep carcinogenesis process in sporadic and hereditary CRC (Saif and Chu 2010).”
BackgroundCrystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 Å
Mimasu, S., Sengoku, T., Fukuzawa, S., Umehara, T., & Yokoyama, S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.066 · Cited by 150 · cited 1×
“It is composed of several domains, including a SWIRM domain, a conserved motif shared by many chromatin regulatory complexes, an amine oxidase domain and a Tower domain found in BRCA2 (Shi and Whetstine 2007; Mimasu et al. 2008; Yang et al. 2007).”
BackgroundMiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells
Shen, W.-W., Zeng, Z., Zhu, W.-X., & Fu, G.-H. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1037-x · Cited by 137 · cited 1×
“found that microRNA-142-3p (miR-142-3p) inhibits the expression of LGR5 in colon cancer cells and OCT4 suppressed miR-142-3p (Shen et al. 2013).”
BackgroundPluripotent Stem Cell Protein Sox2 Confers Sensitivity to LSD1 Inhibition in Cancer Cells
Zhang, X., Lu, F., Wang, J., Yin, F., Xu, Z., Qi, D., Wu, X., Cao, Y., Liang, W., Liu, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.018 · Cited by 119 · cited 2×
“LSD1 and its inhibitor have been reported to target cancer stem cell markers in several cancers (Wang et al. 2011; Zhang et al. 2013; Amente et al. 2013).”
BackgroundSelf-citationExpression of Cyr61, CTGF, and WISP-1 Correlates with Clinical Features of Lung Cancer
Chen, P.-P., Li, W.-J., Wang, Y., Zhao, S., Li, D.-Y., Feng, L.-Y., Shi, X.-L., Koeffler, H. P., Tong, X.-J., & Xie, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000534 · Cited by 115 · cited 1×
“The expression of LSD1 has been associated with tumor recurrence during therapy in various cancers (Lim et al. 2010; Hayami et al. 2011; Chen et al. 2007).”
BackgroundJie, D., Zhang, Z., Guoqing, L., Sheng, L., Zhang, Y., Jing, W., & Zeng, L. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2552-2 · Cited by 103
Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer
Hsu, H., Liu, Y., Tseng, K.-C., Hsu, C., Liang, Y. J., Yang, T., Chen, J., Tang, R., Chen, S., & Chen, H. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1721-x · Cited by 96 · cited 4×
“1 3 ability, while overexpression of Lgr5 in CRC cells increased cell proliferation (Hsu et al. 2013).”
BackgroundMethodInfluentialSelf-citationSimões, H. G., Asano, R. Y., Sales, M. M., Browne, R. A. V., Arsa, G., Motta‐Santos, D., Puga, G. M., Lima, L. C. D. J., Campbell, C. S. G., & Franco, O. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080348 · Cited by 91
Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer
Liu, Y., Hsu, H., Tseng, K.-C., Chen, H., & Chen, S. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.08.001 · Cited by 70 · cited 1×
“Our study revealed that LSD1 is involved in CRC tumorigenesis by up-regulating the expression of LGR5, a functional CRC stem cell marker, which had been confirmed to promote cancer stemness in CRC cells in our previous study (Liu et al. 2013).”
ResultSelf-citationHuang, Z., Li, S., Song, W., Li, X., Li, Q., Zhang, Z., Han, Y., Zhang, X., Miao, S., Du, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070077 · Cited by 70
Wu, C., Hsieh, C., Huang, K., Chang, C., & Kang, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.27343 · Cited by 62 · cited 1×
“The dysregulation of LSD1 activity in human has already been confirmed in several cancers (Lim et al. 2010; Wu et al. 2012; Schenk et al. 2012; Lv et al. 2012; Kauffman et al. 2011; Schutle et al. 2009; Huang et al. 2007).”
BackgroundThe Vienna classification applied to colorectal adenomas
Rubio‐Terres, C., Nesi, G., Messerini, L., Zampi, G., Mandai, K., Itabashi, M., & Takubo, K. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04258.x · Cited by 56 · cited 1×
“The adenoma described in the present study belonged to adenoma with low-grade dysplasia (most common adenoma, Category 3) according to Vienna classification of gastrointestinal epithelial neoplasia (Rubio et al. 2006).”
BackgroundMolecular basis of colorectal cancer: Towards an individualized management?
Perea, J., Lomas, M., & Hidalgo, M. M. (2011) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082011000100006 · Cited by 45
Huang, E., Bi, Y., Jiang, W., Luo, X., Yang, K., Gao, J.-L., Gao, Y., Luo, Q., Shi, Q., Kim, S. H., et al. (2013) · PLoS ONE · doi:10.1371/annotation/2f1c6442-0ecb-4a33-9534-aae89b5fbbc1 · Cited by 44
Chang, K., Kao, H., Yen, T., Chang, Y., Liang, Y. J., Liu, S.-C., Lee, L., Chang, Y., Kang, C., Chen, I., et al. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.11.012 · Cited by 36
Targeting Aberrant Chromatin Structure in Colorectal Carcinomas
Konishi, K., & Issa, J. J. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31803c72fe · Cited by 26 · cited 1×
“Aberrant histone modifications have been shown to contribute to cancer initiation and progression by altering the pattern of gene transcription such as inactivating tumor suppressor genes (Konishi and Issa 2007) and by inducing genome instability due to direct effects in the higher order of chromatin, chromosome conde…”
Background
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
Recent Progress in Histone Demethylase Inhibitors
McAllister, T. E., England, K. S., Hopkinson, R. J., Brennan, P. E., Kawamura, A., & Schofield, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01758 · Cited by 186
Miller, S. A., Policastro, R. A., Sriramkumar, S., Lai, T., Huntington, T. D., Ladaika, C. A., Kim, D., Hao, C., Zentner, G. E., & O'Hagan, H. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3562 · Cited by 176
“Consistent with reports of LSD1 overexpression in colorectal cancer (36), LSD1 expressionwas elevated in our cell lines compared to the normal colon (Supplementary Fig.”
BackgroundLSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials
Noce, B., Bello, E. D., Fioravanti, R., & Mai, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1120911 · Cited by 166
“In further studies, CBB1003 displayed weak cell growth inhibition (IC50 = 250 μM) in colorectal cancer (CRC) through downregulation of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a CRC stem cell marker involved in carcinogenesis (Hsu et al., 2015).”
BackgroundHistone Modifications and their Role in Colorectal Cancer (Review)
Qin, J., Wen, B., Liang, Y., Yu, W., & Li, H. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00663-8 · Cited by 141
“CRC cell growth through down-regulating LGR5 levels and inactivates theWnt/β-catenin pathway [77].”
Background
Metadata
- Authors
- Hsu, H.-C., Liu, Y.-S., Tseng, K.-C., Yang, T.-S., Yeh, C.-Y., You, J.-F., Hung, H.-Y., Chen, S.-J., & Chen, H.-C.
- Affiliations
- Chang Gung Memorial Hospital (TW)
- Chang Gung University (TW)
- Corresponding author
- Chen, Hua-Chien
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2014-07-25
- Volume
- 141
- Issue
- 1
- Pages
- 11-21
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC11824148
- OpenAlex
- W2045771334
- Cited by
- 29
- References
- 42
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 5 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 2 · 2015: 3
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chang Gung Medical Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- LSD1, LSD1 inhibitors, colorectal cancer, Lgr5, colorectal cancer stem cells, Wnt/β-catenin signaling, c-Myc, tumor cell proliferation, metastasis, colorectal adenoma
- MeSH terms
- Adenoma, Adult, Aged, Aged, 80 and over, Amidines, Cell Cycle, Colon, Enzyme Inhibitors, Female, Humans, Immunoenzyme Techniques, Male, Middle Aged, Neoplasm Staging, Piperazines, Rectum, RNA, Messenger, Tumor Cells, Cultured, Blotting, Western, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, Reverse Transcriptase Polymerase Chain Reaction, RNA, Small Interfering, Receptors, G-Protein-Coupled, Cell Proliferation, Histone Demethylases, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.